Theramex launches osteoporosis drug Livogiva in Europe
pharmafile | January 18, 2021 | News story | Sales and Marketing | Theramex, osteoporosis
Theramex, a London-headquartered pharmaceutical company dedicated to women’s health, has launched osteoporosis medicine Livogiva to patients in Europe for the first time.
Livogiva is a new presentation of teriparatide, the only bone anabolic treatment for osteoporosis, which has been developed as a pre-filled pen making it easy to use for patients at high risk of fractures. The treatment has been launched initially in Germany, with availability in other EU countries – including France, Italy and Spain – soon to follow.
Osteoporosis, a condition that causes bones to fracture and break easily, remains largely underdiagnosed and undertreated across Europe. Among those aged over 50 years, one in three women and one in five men will suffer a fragility fracture. Hip, spine and wrist fractures are the most common fractures, which have a debilitating impact on daily activities and quality of life.
Livogiva is a biosimilar of the reference medicine Forsteo (teriparatide), and therapeutic equivalence has been demonstrated in a Phase III clinical study in patients with severe osteoporosis who were treated for six months. Teriparatide is made up of the active sequence of human parathyroid hormone, and stimulates bone formation by acting directly on osteoblasts.
Dr Friederike Eva Thomasius of the Frankfurt Institute of Bone Health in Germany, said: “With osteoporosis still recognised as being hugely under treated, we welcome any new possibility that will expand the therapy options available to patients.
“As Livogiva can be administered by the patients themselves via the pre-filled pen, this has the potential to reduce the number of hospital and osteoporosis centre visits as well as reducing the burden on nursing staff, saving precious hospital and general medical resources.”
Darcy Jimenez
Related Content
SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended …
The Problem of Endometriosis in the UK
When did we decide it was an acceptable condition of womanhood in the UK to …
Biocon Biologics gains EU approval for bone health therapies
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab …
